|
イシヤマ ユウダイ
Ishiyama Yuudai
石山 雄大 所属 医学部 医学科（東京女子医科大学病院） 職種 助手 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. |
| 掲載誌名 | 正式名：Anticancer research 略 称：Anticancer Res ISSNコード：02507005/17917530 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 41(3),pp.1607-1614 |
| 著者・共著者 | ISHIYAMA Yudai†, KONDO Tsunenori*, NEMOTO Yuki, KOBARI Yuki, ISHIHARA Hiroki, TACHIBANA Hidekazu, YOSHIDA Kazuhiko, HASHIMOTO Yasunobu, TAKAGI Toshio, IIZUKA Junpei, TANABE Kazunari |
| 担当区分 | 筆頭著者 |
| 発行年月 | 2021/03 |
| 概要 | BACKGROUND/AIM:We investigated the prognostic nutritional index (PNI), comprised of lymphocytes and albumin, as a potential prognosticator of metastatic urothelial carcinoma (mUC) patients receiving pembrolizumab.PATIENTS AND METHODS:Sixty-five patients were retrospectively enrolled and classified as low (<40) and high (≥40) based on pretreatment PNI. Progression-free survival (PFS), overall survival (OS) and response rates were evaluated.RESULTS:In the low PNI group, significantly shorter PFS and OS were observed. PNI was shown to be an independent predictor of PFS and OS in the multivariate analysis. C-index for both PFS and OS improved with the addition of PNI to the model described in the KEYNOTE-045 study. Significantly more patients experienced initial disease progression in the low PNI group.CONCLUSION:PNI is a useful predictor of prognosis and disease progression in mUC patients receiving pembrolizumab. |
| DOI | 10.21873/anticanres.14922 |
| PMID | 33788756 |